Novartis AG Mayzent FDA Approval Investor Call Transcript
Good morning and good afternoon, and welcome to the Mayzent FDA Approval Conference Call and Live Audio Webcast. (Operator Instructions) The conference is being recorded. (Operator Instructions)
With that, I would like to hand over to Mr. Pierre-Michel Bringer, Investor Relations Officer. Please go ahead, sir.
Okay, thank you. Good morning, good afternoon, everybody. This is Pierre-Michel from Investor Relations. Thank you for joining us today to discuss the approval of Mayzent, an important addition to our MS franchise and particularly important for people with MS.
Joining me today are Paul Hudson, CEO of Novartis Pharmaceuticals; Danny Bar-Zohar, Development Head, Neuroscience unit. Both Paul and Danny will make some opening comments, following which we'll take your questions. Note that we plan to finish around 1:30, which is in about 45 minutes from now.
Before turning the call over to Paul, I would like to remind you that the information presented today
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
